Trust Co. of Vermont Has $11.81 Million Position in Pfizer Inc. (NYSE:PFE)

Trust Co. of Vermont grew its stake in Pfizer Inc. (NYSE:PFE) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 408,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,243 shares during the period. Trust Co. of Vermont’s holdings in Pfizer were worth $11,811,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in PFE. Marshall Wace LLP boosted its stake in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB acquired a new stake in shares of Pfizer in the 1st quarter valued at approximately $172,902,000. Pzena Investment Management LLC boosted its stake in shares of Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Pfizer by 21.8% in the 1st quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after purchasing an additional 2,829,178 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its stake in shares of Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after purchasing an additional 2,487,919 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 1.3 %

Shares of NYSE PFE opened at $29.28 on Friday. The company has a market capitalization of $165.89 billion, a P/E ratio of -487.92, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $32.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company’s 50 day moving average price is $29.05 and its 200-day moving average price is $28.42.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.74%. Pfizer’s payout ratio is presently -2,800.00%.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. UBS Group lifted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday. They set a “market perform” rating and a $32.00 target price on the stock. Barclays lifted their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.